



**HLA-B27-FITC / HLA-B7-PE**

Ref: CYT-COMB1012



**For Research Use Only. Not for use in diagnostic procedures**

#### **INTENDED USE**

CYT-COMB1012 is a pre-mixed cocktail of 2 conjugated monoclonal antibodies: anti-HLA-B27 labelled with fluorescein isothiocyanate (FITC) and anti-HLA-B7 labelled with R-phycerythrin (PE). This reagent is designed for use as a direct immunofluorescence reagent in the identification and enumeration of HLA-B27 antigen-expressing cells.

#### **SUMMARY AND EXPLANATION**

Flow Cytometry (FC) is a powerful tool in analytical and quantitative characterization of cells which provides rapid and multiparametric analysis of heterogeneous cell populations on a cell-by-cell basis. FC is performed on cell suspension after incubating it with fluorescent-labelled antibodies directed against specific cellular proteins. Positive cells relative fluorescence intensity indicates the amount of antibody bonded to specific cell sites providing information about antigen expression.

Human Leukocyte Antigen (HLA) B27 is a class I surface antigen encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides to T cells. HLA-B7-PE antibody binds to the HLA-B7 antigen and does not cross react with HLA-B27 or other related HLA antigens. HLA-B27 and HLA-B7 antigens are expressed in 7% and 22% of individuals of Caucasian origin<sup>(1,2)</sup>.

This mixture of antibodies permits the characterization of HLA-B27 specificity in the HLA class I allotype in patients suffering from inflammatory disorders affecting the sacroiliac and intervertebral joints. This finding aids in the diagnosis of ankylosing spondylitis 90% of sufferers of which express the HLA-B27 antigen, versus 7% in the normal population<sup>(3-6)</sup>. HLA-B27-PE antibody can be used to distinguish true HLA-B27 positives (HLA-B27+/HLA-B7-) from false HLA-B27 positives (HLA-B27dim+/HLA-B7+)<sup>(7)</sup>

#### **PROCEDURE PRINCIPLES**

FC is an innovative technology that can evaluate simultaneously different characteristics for a single cell. Flow cytometers use hydrodynamic focusing to individually present cells to one or more laser beams. As cells are intercepted by light a set detectors recover signals of two different kinds: those generated by dispersed light (FSC/SSC), which mainly reflect cell size and internal complexity, and those related to fluorochromes light emission when cells are labelled. Recovered signals are then amplified by a series of linear and logarithmic amplifiers and converted in electrical signals large enough to be plotted graphically.

Fluorochrome-labelled monoclonal antibodies bind specific antigens, therefore cell populations carrying this antigen will be detected when the reagent is added to a sample and passed through a flow cytometer.

Detection of targeted populations can be hindered by erythrocytes presence. This problem can be avoided by their removal using a red blood cell lysing solution previous to sample acquisition. Quicklysis™ (CYT-QL-1) erythrocyte lysing solution without fixatives is recommended since it requires no washing steps. Quicklysis™ use minimises sample handling and avoids centrifuge processed which are usually associated to cell losses<sup>(8,9)</sup>.

HLA-B27+/HLA-B7- is expressed as a percentage of total lymphocytes present in a sample. Since every flow cytometer has different operating characteristics each laboratory must determine its optimal operating procedure.

#### **REAGENT COMPOSITION**

CYT-COMB1012 is provided in phosphate buffered saline with ≤0.09% (m/v) sodium azide. It contains:

- Purified monoclonal HLA-B27 Antibody conjugated with fluorescein isothiocyanate (FITC). Clone: HLA-ABC-m3. Isotype: IgG2a.
- Purified monoclonal HLA-B7 Antibody conjugated with R-phycerythrin (PE). Clone: BB7.1. Isotype: IgG1.

Amount per 1 ml vial: 100 tests (10 µl mAb per determination).

Reagent is considered non-sterile.

#### **STORAGE CONDITIONS**

The reagent is stable when stored at 2-8 °C until expiration date shown on label. The reagent should not be frozen or exposed to direct light during storage or during cell incubation. Reagent vial should be kept dry and once open stored in vertical position to avoid any possible spillage.

#### **WARNINGS AND RECOMMENDATIONS**

1. For Research Use Only. Not for use in diagnostic procedures.
2. This product is supplied ready to use, any modification by dilution or addition of other compounds should be validated by the user.
3. The reagent is stable until its expiry date when properly stored. Do not use it after expiration date shown on label. If product is stored in conditions different from those recommended, such conditions must be validated by the user.
4. Alteration in reagent appearance, such as precipitation or discoloration indicates instability or deterioration. In such cases, the reagent should not be used.
5. It contains 0,09% (m/v) sodium azide (CAS-No. 26628-22-8) as a preservative, but even so care should be taken to avoid microbial contamination of reagent or incorrect results may occur.

#### **Indication(s) of danger:**

H302 Harmful if swallowed

#### **Safety advice:**

- |           |  |
|-----------|--|
| P264      | Wash thoroughly after handling.  |
| P270      | Do not eat, drink or smoke when using this product.  |
| P301+P312 | If swallowed, call a poison center or doctor/physician if you feel unwell.                         |
| P301+P330 | If swallowed, rinse mouth.   |
| P501      | Dispose of contents/container in accordance with local/regional/national/international regulation. |
6. All patient specimens and materials are considered biohazards and should be handled as if capable of transmitting infection<sup>(10)</sup>. Disposal should be made according to the established legal precautions. It is also recommendable the use of appropriate protective

- gloves and clothing when handling this product. Product use should be made by personnel qualified to perform the described procedures. Avoid sample contact with skin or mucous membranes. Wash immediately with abundant water if skin contact has occurred.
7. Reagent use with incubation times or temperatures different from those recommended may cause erroneous results. Any changes in procedure must be validated by the user.

## PROCEDURE

### **Material included**

HLA-B27-FITC/HLA-B7-PE can be used for 100 determinations (10 µl mAb per determination).

### **Material required but not included**

- 488 nm ion argon laser-equipped flow cytometer and appropriate computer hardware and software.
- Test tubes suitable for the used flow cytometer. Usually 6 mL tubes (12x 75 mm) with a rounded bottom are used.
- Automatic pipette (100µL) and tips.
- Micropipette and tips.
- Chronometer.
- Vortex Mixer.
- Isotypic control reagent.
- Quicklysis™ lysing solution.
- Wash buffer (phosphate buffered saline (PBS) containing ≤0.09% (m/v) sodium azide).

### **Preparation**

Whole blood sample must be taken aseptically by venipuncture <sup>(11, 12)</sup> in a sterilized tube containing an appropriate anticoagulant (use of EDTA is recommended). FC analysis require 100 µL whole blood sample per tube, assuming a normal range of approximately 4 to 10 x 10<sup>3</sup> leucocytes per µL. Samples with high white blood cell count should be diluted with PBS to obtain an approximate cell concentration of 1 x 10<sup>4</sup> cells/µL. Store blood samples at 18-22°C until they are to be tested. It is advisable to test blood samples within 24 hours after their extraction. Samples with suspended cell aggregates or haemolysed should be rejected. Recommended procedure:

1. Spin down the vial before each use.
2. Mix 100µL of peripheral blood with 10µl HLA-B27-FITC/HLA-B7-PE. In case of working with other body fluids with fewer cells, such as cerebrospinal fluid, bronchoalveolar lavage, gastric lavage, etc., start with an initial volume of 200 µL.
3. To evaluate non-specific binding of the antibody, an appropriated isotype control tube can be prepared.
4. Incubate in the dark at room temperature for 15 minutes.
5. Add 2 mL of Quicklysis™ erythrocyte lysing solution and incubate sample in the dark at room temperature for 10 minutes.
6. Acquisition in the flow cytometer should be performed within the first four hours after sample preparation. If samples are not acquired immediately after preparation, they should be stored in the dark at 2-8°C. Instrument calibration must be done according to manufacturers' advice. Before acquiring samples, adjust threshold or discriminator to minimise debris and ensure that populations of interest are included. Also, previous to acquisition samples should be mixed on a vortex (low speed) to reduce cell aggregation.

\*Note: The use of other lysing solutions may require elimination of lysed red blood cells. Follow lysing solution manufacturer recommended protocol.

### **Flow cytometry analysis**

Confirm that the cytometer is correctly aligned and standardised for light dispersion and fluorescent intensity. Compensation should be set following cytometer manufacturer instructions.

Interpretation of results:

- If the lymphocytic populations show an immunophenotype HLA-B27+/HLA-B7<sup>-</sup> sample can be considered as being HLA-B27 positive.
- If the lymphocytic populations show an immunophenotype HLA-B27/HLA-B7<sup>-</sup> or HLA-B27/HLA-B7<sup>+</sup> sample can be considered as being HLA-B27 negative.
- If the lymphocytic populations show an immunophenotype HLA-B27<sup>dim+</sup>/HLA-B7<sup>+</sup> sample has a high probability of being HLA-B27 positive. However, a confirmatory microlymphcytotoxicity test or using PCR is recommended.
- If the lymphocytic populations show an immunophenotype HLA-B27<sup>+</sup>/HLA-B7<sup>dim+</sup> sample has a high probability of being HLA-B27 negative. However, a confirmatory microlymphcytotoxicity test or using PCR is recommended.

### **LIMITATIONS**

- Blood samples should be stored at 18-22°C and tested within 24 hours after they were obtained.
- It is advisable to acquire stained samples as soon as possible to optimise results. Non-viable cells may show unspecific staining. Prolonged exposure of whole blood samples to lytic reagents may cause white cell destruction and targeted population cell loss.
- When using whole blood procedures some red blood cells may not lyse, for instance if there are nucleated red blood cells or if abnormal protein concentration and haemoglobinopathies are observed. This may cause misleading results since unlysed red blood cells are counted as leucocytes.
- Results obtained by FC may be erroneous if cytometer laser is misaligned or if gates are incorrectly set.
- Each laboratory should establish a normal range for HLA-B27+ using its own test conditions.
- Certain patients may present special problems due to altered or very low number of a certain cellular population.
- Cells separated from whole blood by means of density gradients may not have the same relative concentration as in whole blood. This may be relatively insignificant in individuals with normal white blood cell counts. In leucopenic patients, the selective loss of specific subsets may affect determination accuracy.
- Knowledge of antigen normal expression pattern and its relation to other relevant antigens is paramount to carry out an adequate analysis <sup>(1-7, 13)</sup>.
- Abnormal states of health are not always represented by abnormal percentages of certain leucocyte populations. An individual in an abnormal state of health may show the same leucocyte percentage as a healthy person.

### **QUALITY CONTROL**

- Pipettes precision and cytometer calibration should be verified to obtain optimal results.

- In multicolour panels, fluorochromes emit in wavelengths that can show certain spectral overlap which must be corrected by electronic compensation. Optimal compensation levels can be established by analysing cells from healthy individuals stained with mutually exclusive monoclonal antibodies conjugated with appropriate fluorochromes.
- Non-specific binding of the antibody can be evaluated using an appropriated isotype control tube.

#### **REFERENCES**

1. Colombani J. HLA - Fonctions immunitaires et applications médicales. John Libbey Eurotext., pp 285 (1993).
2. Lee TD. Distribution of HLA antigens: distribution of HLA antigens in north american caucasians, north american blacks and orientals. The HLA system, a new approach. Chap 6,John Lee Editor, 141-236. (1990).
3. Fizet D. Identification de l'antigène HLA B27 par cytométrie de flux. Ann. Bilo. clin. 47: 408-411 (1989).
4. Feltkamp TEW, Khan MA, Lopez de Castro JA. The pathogenetic role of HLA-B2. Immunol. Today, 1 (17): 5-7.(1996)
5. Bodmer J. World distribution of HLA alleles and implications for disease. Ciba Foundation Symposium. 197: 233-258. (1996).
6. Lopez-Larrea C, Gonzalez-Roces S, Alvarez V. HLA-B27 structure, function and disease association. Curr. Opin. Rheumatol., 8: 296-308 (1996).
7. Brodsky FM et al. Monoclonal antibodies for analysis of the HLA system. Imm. Reviews 47: 3-61 (1979).
8. Menéndez P, et al. Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. Cytometry (Comm. Clin. Cytometry) 34: 264-271 (1998)
9. Gratama JW, Menéndez P, Kraan J, Orfao A. Loss of CD34+ hematopoietic progenitor cells due to washing can be reduced by the use of fixative-free erythrocyte lysing reagents. J Immunol. Methods 239: 13-23 (2000)
10. Protection of Laboratory Workers from occupationally acquired infections. Second edition; approved guideline (2001). Villanova PA: National Committee for Clinical Laboratory Standards; Document M29-A2.
11. Procedures for the collection of diagnostic blood specimens by venipuncture- approved standard; Fifth edition (2003). Wayne PA: National Committee for Clinical Laboratory Standards; Document H3-A5.
12. Clinical applications of flow cytometry: Quality assurance and immunophenotyping of lymphocytes; approved guideline (1998). Wayne PA: National Committee for Clinical Laboratory Standards; Document H42-A.
13. Bowness P. HLA B27 in health and disease: a double-edged sword?. Rheumatology 41: 857-868 (2002).

#### **WARRANTY**

This product is warranted only to conform to quantity and label specifications. There are no warranties that extend beyond the description on product label. Cytognos' sole liability is limited to either product replacement or refund of the purchase price.

#### **EXPLANATION OF SYMBOLS**

|  |  |
|--|--|
|  | Use by (YYYY-MM)                           |
|  | Catalogue number                           |
|  | Batch code                                 |
|  | Keep out of sunlight                       |
|  | Storage temperature limitation             |
|  | Consult instructions for use               |
|  | Manufacturer                               |
|  | For research use only                      |
|  | Contains sufficient for <n> tests          |
|  | Health hazard/Hazardous to the ozone layer |

#### **PRODUCED BY**

#### **CYTOGNOS SL**

Polígono La Serna, Nave 9  
 37900 Santa Marta de Tormes  
 Salamanca (Spain)  
 Phone: + 34-923-125067  
 Fax: + 34-923-125128  
 Ordering information: [admin@cytognos.com](mailto:admin@cytognos.com)  
 Technical information: [support@cytognos.com](mailto:support@cytognos.com)

[www.cytognos.com](http://www.cytognos.com)